Literature DB >> 6640839

Mechanisms of action of intravesical treatment. Effect on the ABH surface antigens of urothelial cells.

G Jakse, F Hofstädter.   

Abstract

Blood group isoantigens can be demonstrated immune-histologically on normal urothelium of the urinary bladder by means of the specific red cell adherence test. In preneoplastic and reactive changes of the urothelium and in dysplasia and carcinoma in situ, there is a loss of these antigens. Ultrastructural investigations of carcinoma in situ demonstrate a loss of normal membrane structures such as tight junctions, desmosomes, and glycocalyx. Of 18 patients with carcinoma in situ of the urinary bladder, 12 achieved tumor remission after topical chemotherapy with doxorubicin hydrochloride. A recurrence of blood group isoantigens was demonstrated in patients who achieved tumor remission. The antigenicity reappears before complete normalization of the urothelium. Ultrastructural investigations demonstrated normalization of cellular membrane structures in the respective biopsies. According to these findings and the current literature, the mechanisms of action of doxorubicin hydrochloride in carcinoma in situ may be due to retardation of cell cycle, cell loss by desquamation, cell death, and decrease of growth fraction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6640839

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

Review 1.  Fucolipids and blood group glycolipids in normal and tumor tissue.

Authors:  S Hakomori
Journal:  Prog Biochem Pharmacol       Date:  1975

2.  The distribution of the blood group. A antigen in human tissues.

Authors:  E J HOLBOROW; P C BROWN; L E GLYNN; M D HAWES; G A GRESHAM; T F O'BRIEN; R R COOMBS
Journal:  Br J Exp Pathol       Date:  1960-08

3.  Early immunologic diagnosis and prognosis of carcinoma. Philip Levine Award Address.

Authors:  I Davidsohn
Journal:  Am J Clin Pathol       Date:  1972-06       Impact factor: 2.493

4.  Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response.

Authors:  D Kessel; V Botterill; I Wodinsky
Journal:  Cancer Res       Date:  1968-05       Impact factor: 12.701

5.  Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years.

Authors:  A Bergkvist; A Ljungqvist; G Moberger
Journal:  Acta Chir Scand       Date:  1965-10

6.  Selective loss of blood group antigens during wound healing.

Authors:  E Dabelsteen; I Mackenzie
Journal:  Acta Pathol Microbiol Scand A       Date:  1976-11

7.  Tissue blood-group antigens and prognosis in low stage transitional cell carcinoma of the bladder.

Authors:  P H Lange; C Limas; E E Fraley
Journal:  J Urol       Date:  1978-01       Impact factor: 7.450

8.  Isoantigens A, B and H in urinary bladder carcinomas following radiotherapy.

Authors:  J Alroy; K Teramura; A W Miller; B U Pauli; J E Gottesman; M Flanagan; I Davisohn; R S Weinstein
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

9.  Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: a followup.

Authors:  G Jakse; F Hofstädter; H Marberger
Journal:  J Urol       Date:  1984-01       Impact factor: 7.450

10.  Blood group isoantigen deletion in carcinoma in situ of the urinary bladder.

Authors:  R S Weinstein; J Alroy; G M Farrow; A W Miller; I Davidsohn
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

View more
  1 in total

Review 1.  Targeting Hsp90 in urothelial carcinoma.

Authors:  Mahmoud Chehab; Tiffany Caza; Kamil Skotnicki; Steve Landas; Gennady Bratslavsky; Mehdi Mollapour; Dimitra Bourboulia
Journal:  Oncotarget       Date:  2015-04-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.